ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This trial tests a non‑invasive capsule that samples the small intestine directly to search for microbial or metabolite signatures linked to symptoms and disease. If successful, it could help researchers identify small‑bowel dysbiosis biomarkers relevant to IBD and other gut disorders.
Who Should Pay Attention
Patients with Crohn’s disease or ulcerative colitis, people with IBS or suspected small‑bowel microbiome issues, microbiome researchers, and clinicians interested in diagnostic biomarkers.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment300 participants
Study statusActive_not_recruiting
Source depthTrial registry record
What To Know
The ClinicalTrials.gov record describes an observational study testing the SIMBA ingestible fluid‑biopsy capsule, which mechanically collects small‑intestinal fluid for metagenomic and metabolomic analysis.
Participants (including people with Crohn’s disease, ulcerative colitis, IBS, celiac disease, and healthy controls) swallow up to four capsules and provide stool samples plus symptom and lifestyle questionnaires.
The primary aim is to look for correlations between small‑bowel microbial/metabolite patterns and gastrointestinal disease states to identify potential dysbiosis biomarkers. The study is observational and not testing a drug or therapy; it focuses on sample collection and lab analysis (metagenomics, metabolomics) to seek diagnostic or research biomarkers.
Enrollment is planned for up to 300 participants at a single site in Calgary, Canada, and the record is listed as active, not recruiting.
Keep In Mind
Registry entry describes study design, eligibility, and planned analyses but does not report results. This is an observational biomarker discovery study at one site; findings would need independent validation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorNimble Science Ltd.
Trial IDNCT05633706
Study typeObservational
Enrollment300 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedSep 30, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Researchers planned to study whether patterns in the gut microbiome correlate with clinical diagnoses (including Crohn’s and UC), which could inform future biomarker work. The study is suspended, so no results are...
Machine Learning Model Identifies Gut Biomarkers That May Help Diagnose IBD Patients
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
The study aims to map the specific peptide targets of T cells driving organ inflammation in autoimmune diseases, which could guide development of antigen-specific, tolerogenic treatments relevant to Crohn's disease and...